About the Company
In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention." More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular. A biomarker can be a substance that is introduced into an organism as a means to examine organ function or other aspects of health. For example, rubidium chloride is used in isotopic labeling to evaluate perfusion of heart muscle. It can also be a substance whose detection indicates a particular disease state, for example, the presence of an antibody may indicate an infection. More specifically, a biomarker indicates a change in expression or state of a protein that correlates with the risk or progression of a disease, or with the susceptibility of the disease to a given treatment. Biomarkers can be characteristic biological properties or molecules that can be detected and measured in parts of the body like the blood or tissue. They may indicate either normal or diseased processes in the body. Biomarkers can be specific cells, molecules, or genes, gene products, enzymes, or hormones. Complex organ functions or general characteristic changes in biological structures can also serve as biomarkers. Although the term biomarker is relatively new, biomarkers have been used in pre-clinical research and clinical diagnosis for a considerable time. For example, body temperature is a well-known biomarker for fever. Blood pressure is used to determine the risk of stroke. It is also widely known that cholesterol values are a biomarker and risk indicator for coronary and vascular disease, and that C-reactive protein (CRP) is a marker for inflammation. Biomarkers are useful in a number of ways, including measuring the progress of disease, evaluating the most effective therapeutic regimes for a particular cancer type, and establishing long-term susceptibility to cancer or its recurrence. Biomarkers characterize disease progression starting from the earliest natural history of the disease. Biomarkers assess disease susceptibility and severity, which allows one to predict outcomes, determine interventions and evaluate therapeutic responses. From a forensics and epidemiologic perspective, biomarkers offer unique insight about the relationships between environmental risk factors. The parameter can be chemical, physical or biological. In molecular terms biomarker is "the subset of markers that might be discovered using genomics, proteomics technologies or imaging technologies. Biomarkers play major roles in medicinal biology. Biomarkers help in early diagnosis, disease prevention, drug target identification, drug response etc. Several biomarkers have been identified for many diseases such as serum LDL for cholesterol, blood pressure, and P53 gene and MMPs as tumor markers for cancer.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SERA News
Sera Prognostics Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
Sera Prognostics, Inc. (SERA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...
Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript
Sera Prognostics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.25. SERA isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.31 per share a year ago. These figures are ...
Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results
SERA PROGNOSTICS, INC. Condensed Balance Sheets (unaudited) (in thousands) December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 3,880 $ 29,878 Marketable securities ...
Sera Prognostics Inc - Ordinary Shares Class A
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. It focuses on developing blood tests to predict the risks of preterm ...
Sera Prognostics, Inc (SERA) Q4 2023 Earnings Call Transcript
Good afternoon and welcome to the Sera Prognostics Conference Call to Review Fourth Quarter Fiscal Year 2023 Results. At this time, all participants are in listen-only mode. We will be ...
Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript
Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript March 20, 2024 Sera Prognostics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.25.
Loading the latest forecasts...